What antipsychotic virtually causes no motor side effects nor prolactin elevations, but has a moderate risk for weight gain and metabolic disturbances?

A. Quetiapine: Quetiapine has a very low risk of extrapyramidal symptoms and prolactin elevation due to its weak D2 receptor antagonism and rapid dissociation from dopamine receptors. However, it carries a moderate risk for weight gain and metabolic changes, making monitoring necessary for long-term use. B. Olanzapine: Olanzapine has a high risk of metabolic disturbances, including significant weight gain, hyperglycemia, and dyslipidemia, along with moderate motor side effects in some patients. Its potent H1 and 5HT2C antagonism contribute to these effects. C. Clozapine: Clozapine also has minimal motor side effects and prolactin elevation but carries a high metabolic risk. It is associated with significant weight gain, insulin resistance, and dyslipidemia, requiring close metabolic monitoring. D. Risperidone: Risperidone has a higher propensity for prolactin elevation and can cause motor side effects such as extrapyramidal symptoms, especially at higher doses. Its metabolic risk is moderate, but the endocrine effects limit its “minimal side effect” profile.